Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 11.31M P/E - EPS this Y 52.30% Ern Qtrly Grth -
Income -3.79M Forward P/E -0.85 EPS next Y -3.10% 50D Avg Chg -36.00%
Sales 174.1k PEG - EPS past 5Y - 200D Avg Chg -21.00%
Dividend N/A Price/Book 0.79 EPS next 5Y - 52W High Chg -60.00%
Recommedations 2.00 Quick Ratio 2.77 Shares Outstanding 6.92M 52W Low Chg 22.00%
Insider Own 26.34% ROA -54.83% Shares Float 5.10M Beta 62.57
Inst Own 13.18% ROE -32.65% Shares Shorted/Prior 58.39K/60.76K Price 2.84
Gross Margin 96.27% Profit Margin - Avg. Volume 75,067 Target Price 12.00
Oper. Margin -2,770.83% Earnings Date Nov 11 Volume 14,187 Change 0.71%
About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs relate to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is based in Melville, New York.

BioRestorative Therapies, Inc. News
11/15/24 BioRestorative Therapies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
11/13/24 BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
11/12/24 BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
11/06/24 BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium
11/05/24 BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
10/31/24 BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program
10/10/24 BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events
10/03/24 BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
09/19/24 BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs
08/13/24 Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Tops Revenue Estimates
08/13/24 BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update
08/06/24 BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024
07/23/24 BioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine
06/27/24 BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
06/17/24 BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
06/13/24 BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program
06/11/24 Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Tops Revenue Estimates
06/04/24 BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference
05/24/24 BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice
05/15/24 BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market
BRTX Chatroom

User Image Benzinga Posted - 4 days ago

BioRestorative Ends Q3 In 'Strong' Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial $BRTX https://www.benzinga.com/partner/biotech/24/11/42086534/biorestorative-ends-q3-in-strong-financial-position-reports-positive-data-for-its-phase-2-brtx-10

User Image SqueezeMyTwits Posted - 6 days ago

$BKKT 84% since my post. 😎 I'm still waiting on my $BRTX

User Image Benzinga Posted - 1 week ago

Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative's Inroads Bringing Its Stem Cell Therapies To Market $BRTX https://www.benzinga.com/partner/biotech/24/11/42009365/presenting-encouraging-data-acquiring-licenses-issuing-patents-and-more-biorestoratives-inroads-b

User Image SqueezeMyTwits Posted - 1 week ago

$BRTX I'll double down here. 😎

User Image Benzinga Posted - 1 week ago

BioRestorative Therapies Lower Back Candidate Shows Decrease In Pain, Increased Function https://www.benzinga.com/general/biotech/24/11/41947266/biorestorative-therapies-lower-back-candidate-shows-decrease-in-pain-increased-function $BRTX

User Image BioTuesdays Posted - 1 week ago

BioRestorative Therapies announced new preliminary 26–52 week blinded data from the first 10 patients with chronic lumbar disc disease (cLDD) enrolled in the ongoing Phase 2 clinical trial of BRTX-100 $BRTX https://biotuesdays.com/2024/11/13/biorestorative-therapies-preliminary-brtx-100-phase-2-data-for-cldd-bolsters-confidence-in-trial-hitting-primary-and-secondary-endpoints/

User Image OpenOutcrier Posted - 1 week ago

$BRTX (+11.6% pre) BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data https://ooc.bz/l/47917

User Image SqueezeMyTwits Posted - 1 week ago

$BRTX With the news out today, any volume could send this. 😎

User Image wonderfulworld Posted - 1 week ago

$BRTX Summary Third Quarter 2024 Results For the quarter ended September 30, 2024, the Company had a loss from operations of $2.3 million, a 26% year-over-year improvement from $3.1 million for the comparable period of 2023, and a 9% improvement sequentially from $2.5 million in the second quarter of 2024. The Company’s net loss for the 2024 third quarter was $1.1 million, or $0.13 per share. The Company ended the third quarter in a very strong financial position, with cash, cash equivalents, and investments held in marketable securities of $13.1 million, with no outstanding debt, as of September 30, 2024

User Image ButterCapital Posted - 1 week ago

$BRTX nibbling

User Image SqueezeMyTwits Posted - 1 week ago

$BRTX I like the chart. I'm in! 😎

User Image StreetwiseReports Posted - 2 weeks ago

Regenerative Med Co. Granted Second Tissue License: https://ow.ly/ILgc50U2KV0 With these expanded capabilities, the biotech may increase revenue generation and continue its clinical trial, noted a Roth MKM report. $BRTX #biotechstocks BioRestorative Therapies Inc

User Image BioTuesdays Posted - 2 weeks ago

BioRestorative to unveil key Phase 2 findings on BRTX-100 for cLDD at ORS PSRS International Spine Research Symposium $BRTX https://biotuesdays.com/2024/11/06/biorestorative-to-unveil-key-phase-2-findings-on-brtx-100-for-cldd-at-ors-psrs-international-spine-research-symposium/

User Image lecorb Posted - 2 weeks ago

$BRTX https://seekingalpha.com/news/4248198-biorestorative-therapies-rises-on-expanded-tissue-license-from-ny-state-health-department?utm_source=quotemedia.com&utm_medium=referral&feed_item_type=news

User Image HitItHard3585 Posted - 2 weeks ago

$BRTX Unnoticed news this morning? Needs volume. Daily and weekly trying to bounce off of support.

User Image BioTuesdays Posted - 10/31/24

BioRestorative expands IP protecting ThermoStem cell-based metabolic disease therapy program $BRTX https://biotuesdays.com/2024/10/31/biorestorative-expands-ip-protecting-thermostem-cell-based-metabolic-disease-therapy-program/

User Image G101SPM Posted - 1 month ago

#SHOWTIME ^ UBS Virtual Organ Restoration Day (October 15) Scheduled to appear: $BRTX, $LGVN, $PROK ^IDWeek Conference (October 15-18) Scheduled to appear: $DEST, $MRK, $SCYX

User Image AlphaTuna Posted - 1 month ago

Lowest Volume Rated General Stocks Per 10/4/2024’s Close: 1 – $BRYFF 2 – $AVCNF 3 – $CTSDF 4 – $CIAFF 5 – $FXLV 6 – $BRTX 7 – $BTSGU 8 – $GIKLY 9 – $BSBK 10 – $XCUR https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-10-4-2024/

User Image Omega_Proxy Posted - 1 month ago

$BRTX let's hope for higher lows....

User Image Omega_Proxy Posted - 1 month ago

$BRTX 😑

User Image BioTuesdays Posted - 1 month ago

BioRestorative’s IFATS presentation features ThermoStem’s potential to deliver a superior efficacy and tolerability profile over GLP-1 drugs $BRTX https://biotuesdays.com/2024/09/25/biorestoratives-ifats-presentation-features-thermostems-potential-to-deliver-a-superior-efficacy-and-tolerability-profile-over-glp-1-drugs/

User Image ChartLaboratory_com Posted - 2 months ago

https://www.tradingview.com/x/fC8W3hK3/ https://www.globenewswire.com/news-release/2024/09/23/2951227/0/en/Black-Diamond-Therapeutics-Announces-Initial-Phase-2-Data-Demonstrating-Robust-Anti-tumor-Activity-of-BDTX-1535-in-Patients-with-Recurrent-EGFRm-NSCLC-who-Present-with-a-Broad-Spec.html $BRTX Trade Setup: Entry: Enter at $5.00 if a pullback holds, or at $5.92 on breakout confirmation. Stop Loss: Place at $4.50 or lower. Take Profit Levels: Partial exit at $7.00, with a final target at $7.66. Summary: With momentum, volume, and technical support aligning, $BRTX presents a solid swing trade setup. The key is to watch support at $4.55-$5.00 and target resistance at $7.00-$7.66. Extension targets $8.00 and $11.66 Make sure to utilize stop losses and manage your risk accordingly below $4.50 ChartLAB Daily: www.patreon.com/chartlab The Best & Trusted Source for Quality Trading Education! Join our community 🔑 Unlock the best trade plan education 📬 exclusive news 📊 in-depth analysis 📡 actionable trades delivered to you every day ChartLAB = realtime success Expert insights and timely alerts Empower your trading decisions Smart Strategies & Education Exclusive Premium Benefits & Newsletter Join today! www.patreon.com/chartlab

User Image HarrisMint Posted - 2 months ago

$BRTX If about $2.20 on this would happen to break, there's room to about $3.00 on it...... Easy 20-30% if that happens? So.. If about $1.77 breaks near term, then it could fall hard enough. Will prob keep stop right below there. Risk about 10% for 20%+

User Image Treton Posted - 2 months ago

$DJT $BRTX up 10%

User Image Treton Posted - 2 months ago

$BRTX Loaded heavy here

User Image Stock_Titan Posted - 2 months ago

$BRTX BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs https://www.stocktitan.net/news/BRTX/bio-restorative-therapies-ifats-2024-presentation-to-feature-thermo-nyi3radsmli8.html

User Image Benzinga Posted - 2 months ago

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind? $BRTX https://www.benzinga.com/partner/biotech/24/09/40789254/armed-with-its-patent-portfolio-biorestorative-therapies-has-success-in-the-laboratory-and-at-the

User Image Omega_Proxy Posted - 08/26/24

$BRTX Thermostem news imminent.

User Image Nyyanks77 Posted - 3 months ago

$BRTX was in this garbage two years ago . All the promise in the world and it’s down 88% . Can you say SCAM?!?! Lol . I feel bad for whoever is sticking to this garbage .

User Image Omega_Proxy Posted - 3 months ago

Which is why I'm holding: $BRTX $NAUT & $GMGMF Life is more fun with a little gamble. I see 100x potential. I'm most bullish on $GMGMF We'll see. Revisit this post in 10 years.

Analyst Ratings
Roth MKM Buy Aug 14, 24
Roth MKM Buy Jun 12, 24
Roth MKM Buy Aug 14, 23
Roth Capital Buy Dec 7, 22
Maxim Group Buy Sep 28, 22
Roth Capital Buy Dec 1, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Broadrick Dale 10% Owner 10% Owner Nov 27 Sell 1.89 278 525 327,295 12/01/23
Broadrick Dale 10% Owner 10% Owner Sep 14 Buy 1.6 20,000 32,000 327,573 09/18/23
Broadrick Dale 10% Owner 10% Owner Jul 27 Buy 2.8 1,000 2,800 306,073 07/28/23
ALSTODT LANCE President, CEO, COB President, CEO, COB Jul 25 Buy 2.44 4,200 10,248 184,418 07/25/23
Silva Francisco VP of Research and D.. VP of Research and Development Mar 31 Buy 3.56 747 2,659 159,690 04/04/23
ALSTODT LANCE President, CEO, COB President, CEO, COB Jan 27 Buy 3.01 200 602 186,921 01/30/23
ALSTODT LANCE President, CEO, COB President, CEO, COB Jan 18 Buy 3.1 400 1,240 186,521 01/20/23
ALSTODT LANCE President, CEO, COB President, CEO, COB Jan 09 Buy 3.08 100 308 186,121 01/10/23
ALSTODT LANCE President, CEO, COB President, CEO, COB Dec 23 Buy 3.01 300 903 186,021 12/28/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Dec 07 Buy 2.9861 1,800 5,375 185,721 12/07/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Nov 18 Buy 2.8765 1,000 2,876 183,921 11/21/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Sep 22 Buy 2.92 200 584 182,921 09/23/22
Silva Francisco VP of Research and D.. VP of Research and Development Aug 26 Buy 3.29 5,723 18,829 12,136 09/09/22
Silva Francisco VP of Research and D.. VP of Research and Development Aug 26 Sell 3.39 3,958 13,418 158,156 09/09/22
Broadrick Dale 10% Owner 10% Owner Jul 06 Buy 3.12 1,200 3,744 298,573 07/15/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jul 12 Buy 2.95 700 2,065 182,721 07/13/22
Broadrick Dale 10% Owner 10% Owner Jun 30 Buy 3.0789 1,900 5,850 297,373 07/05/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jun 30 Buy 3.0981 1,100 3,408 182,021 07/01/22
Broadrick Dale 10% Owner 10% Owner Jun 15 Buy 3.76 3,200 12,032 294,773 06/17/22
Kristal Robert Eugene Chief Financial Offi.. Chief Financial Officer Jun 15 Buy 3.61 194 700 7,994 06/15/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jun 15 Buy 3.6822 700 2,578 180,321 06/15/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jun 14 Buy 3.9119 500 1,956 179,621 06/15/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jun 13 Buy 3.95 200 790 179,121 06/14/22
Broadrick Dale 10% Owner 10% Owner Jun 09 Buy 4.25 1,600 6,800 290,273 06/13/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jun 08 Buy 4.28 100 428 178,921 06/09/22
Broadrick Dale 10% Owner 10% Owner Jun 03 Buy 4.92 4,200 20,664 282,673 06/07/22
Kristal Robert Eugene Chief Financial Offi.. Chief Financial Officer Jun 07 Buy 4.56 200 912 7,800 06/07/22
Broadrick Dale 10% Owner 10% Owner Jun 02 Buy 4.6878 1,000 4,688 278,473 06/06/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jun 01 Buy 4.6 200 920 178,821 06/03/22
Broadrick Dale 10% Owner 10% Owner May 26 Buy 3.51 4,950 17,374 259,303 05/31/22
Broadrick Dale 10% Owner 10% Owner May 26 Sell 3.44 2,000 6,880 257,303 05/31/22
ALSTODT LANCE President, CEO, COB President, CEO, COB May 02 Buy 3.95 400 1,580 175,921 05/02/22
Kristal Robert Eugene Chief Financial Offi.. Chief Financial Officer Apr 08 Buy 5.71 7,600 43,396 7,600 04/11/22
Broadrick Dale 10% Owner 10% Owner Apr 06 Buy 5.66 2,500 14,150 254,353 04/08/22
Broadrick Dale 10% Owner 10% Owner Mar 29 Buy 4.89 15,700 76,773 316,972 04/01/22
Broadrick Dale 10% Owner 10% Owner Mar 01 Buy 4.87 155,950 759,476 205,853 03/29/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jan 24 Buy 3.4 1,470 4,998 163,083 01/24/22